Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.
We report our experience with the use of recombinant activated factor VII (rFVIIa) during cardiac surgery in a 4.5-year-old boy with severe congenital FXI deficiency and a congenital heart disease. After weaning the patient from cardiopulmonary bypass, the first intravenous dose of rFVIIa (90 microg/kg) was administered. This same dosage was repeated eight more times, at 2- to 4-hour intervals postoperatively. There was no bleeding during and after surgery. rFVIIa treatment may be used successfully in children with severe FXI deficiency in major operations such as open heart surgery.
Avci
Zekai
Z
Department of Pediatric Hematology, Baskent University Faculty of Medicine, 6. Cadde, No: 72/3, 06490 Bahcelievler, Ankara, Turkey. zekaiavci@yahoo.com
Malbora
Baris
B
Gokdemir
Mahmut
M
Ozkan
Suleyman
S
Ozbek
Namik
N
D000015:Abnormalities, Multiple / Q000601:surgery*; D002315:Cardiopulmonary Bypass; D002675:Child, Preschool; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D005173:Factor XI Deficiency / Q000151:congenital* / Q000188:drug therapy*; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000601:surgery; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa